Hematology/Oncology

Top Story

Penn program addresses ‘barriers and bias’ unique to women in oncology

Penn program addresses ‘barriers and bias’ unique to women in oncology
November 11, 2019
In the Journals

Antidepressant use linked to slightly increased risk for subdural hematoma

November 11, 2019
Use of selective and nonselective serotonin reuptake inhibitors appeared associated with a small increased risk for subdural hematoma, according to results of a…
FDA News

FDA grants priority review, breakthrough therapy designation to Opdivo-Yervoy combination for HCC

November 11, 2019
The FDA granted the combination of nivolumab and ipilimumab priority review and breakthrough therapy designation for the treatment of patients with advanced…

Avelumab maintenance fails to extend OS in advanced gastric, gastroesophageal junction cancers

November 11, 2019
A randomized phase 3 trial designed to evaluate avelumab as first-line maintenance therapy for patients with unresectable, locally advanced or metastatic HER2-ngative…
Meeting News

Novel bispecific immune cell engager safe, clinically beneficial in HER2-positive tumors

November 10, 2019
NATIONAL HARBOR, Md. — An investigational bispecific T-cell engager appeared safe and demonstrated some clinical activity among patients with HER2-positive solid…
More Headlines »
CME

2019 Texas Oncology Clinical Educational Symposium

This activity is supported by educational grants from AbbVie, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Takeda Oncology; and Verastem, Inc..

Clinical outcomes for advanced cancers continue to improve through the identification as well as the development of…
More »
Video
Meeting News

VIDEO: Initial results of ZUMA-3 trial ‘highly encouraging’ for relapsed, refractory leukemia

July 21, 2019
More »
Resource Centers
European Society for Medical Oncology Congress

European Society for Medical Oncology Congress

CME ABIM MOC

Ace the Case: A 44-Year-Old Man With a History of Melanoma and a New Onset of Brain Metastases

There is no commercial support for this activity.

Ace the Case: A 44-Year-Old Man With a History of Melanoma and a New Onset of Brain Metastases
More »
Current Issues
View the Current Issue
HemOnc Today Cell Therapy Next